Aeterna Zentaris announces last patient last visit in DETECT-trial

Aeterna Zentaris announced the clinical completion of its Phase 3 safety and efficacy study AEZS-130-P02 evaluating macimorelin for the diagnosis of Childhood Onset Growth Hormone Deficiency. The Company confirms that the last patient conducted the last study visit successfully in Europe on June 13, 2024. The DETECT-trial is a multicenter, open-label trial to investigate the efficacy and safety of a single oral dose of 1.0 mg/kg macimorelin acetate as growth hormone stimulation test in pediatric patients with suspected growth hormone deficiency. The study enrolled 100 subjects in Europe and North America. The Company remains on track to report top-line data for the DETECT-trial in Q3 2024.